case_images: PMC11006969_01
case_images: Computed tomography images on admission showed multiple mass shadows (A), and CT images after 15 days of piperacillin-tazobactam anti-infection treatment showed partial resorption of the lung lesions in comparison (B). The lesions continued to resorb after 30 days (C).
case_images: fmed-11-1338247-g001.jpg
case_images: PMC11006969_01_fmed-11-1338247-g001.jpg
case_images: fig1
case_images: Her chest CT showed multiple masses and cavity changes in both lungs (Figure 1A), and the blood culture showed bilateral aerobic bottle growth of Klebsiella pneumonia. During the treatment period, the patient's symptoms gradually improved, and the lesion was partially absorbed on Day 15 upon review of the chest CT (Figure 1B). A repeat chest CT showed continued improvement of the lesion (Figure 1C).
case_images: Facial edema and generalized (face, limbs, and chest) skin rash in our patient.
case_images: fmed-11-1338247-g002.jpg
case_images: PMC11006969_01_fmed-11-1338247-g002.jpg
case_images: fig2
case_images: Three days later, she began to develop a punctate red rash in the front chest and forearm of both upper limbs with pruritic discomfort (Figure 2). The range of the posterior rash expanded to the face and lower limbs (Figure 2), the occipital and mandibular lymph nodes became enlarged, and the body temperature increased to a maximum of 39.5 C.
case_images: Dynamic changes of eosinophil count (A), white blood cell count (B), alanine aminotransferase (C), aspartate aminotransferase (D), and lactate dehydrogenase (E) during hospitalization in our patient.
case_images: fmed-11-1338247-g003.jpg
case_images: PMC11006969_01_fmed-11-1338247-g003.jpg
case_images: fig3
case_images: The patient had a gradual rise in eosinophils to 1.33*109/L, leukocytes to 18.47*109/L, and lymphocytes to 7.70*109/L, as well as a significant increase in abnormal lymphocytes (7%) accompanied by abnormal liver function, with an ALT level of 114 U/L, AST level of 68 U/L, and a gradual rise in LDH to 500 U/L (Figure 3).